Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial
Rebecca A. Burrell(Cancer Research UK Cambridge Center), Richard D. Baird(Cancer Research UK)
Cited by 2
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Tumour heterogeneity and the evolution of polyclonal drug resistance
|Molecular Oncology|2014|419
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
|The Lancet Oncology|2020|351
Genomic profile of advanced breast cancer in circulating tumour DNA
|Nature Communications|2021|95